ArticleEvidence-based complementary and alternative medicine : eCAM2011
Protective Effects of Luteolin on Diabetic Nephropathy in STZ-Induced Diabetic Rats.
Article in Evidence-based complementary and alternative medicine : eCAM, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
63 citing papers in PubMed, 179 citations in OpenAlex.
- Unraveling the therapeutic potential of luteolin in renal pathology: a comprehensive pathway oriented approach.Pharmacological reports : PR · 2026Review
- Gut microbiota and gut-kidney axis in kidney diseases: therapeutic potential and perspectives of natural products.Frontiers in pharmacology · 2026Review
- A Mechanism-based Perspective on the Use of Flavonoids in the Treatment of Diabetes and its Complications.Current diabetes reviews · 2026Review
- Therapeutic Potential of Luteolin for Diabetes Mellitus and Its Complications.Chinese journal of integrative medicine · 2025Review
- Luteolin mitigates hippocampal damage in a rat model of streptozotocin-induced diabetes.Biomolecules & biomedicine · 2025Article
- Beneficial effects of food-medicine homologous herbs for patients with diabetic kidney disease.Frontiers in immunology · 2025Review
- Adjunctive effects of intermittent fasting and exercise with glibenclamide on diabetic nephropathy in rats: a potential role of the polyol pathway.Frontiers in physiology · 2025Article
- Natural Compounds in Kidney Disease: Therapeutic Potential and Drug Development.Biomolecules & therapeutics · 2025Review
- Gastrodin ameliorates diabetic nephropathy by activating the AMPK/Nrf2 pathway.Journal of molecular histology · 2024Article
- Antiapoptotic and antinociceptive effects ofResearch in pharmaceutical sciences · 2024Article
- Luteolin suppresses oral carcinoma 3 (OC3) cell growth and migration via modulating polo-like kinase 1 (PLK1) expression and cellular energy metabolism.Journal of Zhejiang University. Science. B · 2023Article
- Application of the Mannich reaction in the structural modification of natural products.Journal of enzyme inhibition and medicinal chemistry · 2023Review
- Effect of Prunetin on Streptozotocin-Induced Diabetic Nephropathy in Rats - a Biochemical and Molecular Approach.Biomolecules & therapeutics · 2023Article
- Oxidative stress and inflammation in diabetic nephropathy: role of polyphenols.Frontiers in immunology · 2023Review
- Effect ofJournal of diabetes and metabolic disorders · 2022Article
- An In-Silico Identification of Potential Flavonoids against Kidney Fibrosis Targeting TGFβR-1.Life (Basel, Switzerland) · 2022Article
- Tenovin-1 Ameliorates Renal Fibrosis in High-Fat-Diet-Induced Diabetic Nephropathy via Antioxidant and Anti-Inflammatory Pathways.Antioxidants (Basel, Switzerland) · 2022Article
- Evaluation of Diabetes Effects of Selenium Nanoparticles Synthesized from a Mixture of Luteolin and Diosmin on Streptozotocin-Induced Type 2 Diabetes in Mice.Molecules (Basel, Switzerland) · 2022Article
- Article
- Use of haematological signatures in conjunction with conventional biomarkers to assess Reno-protective effects of Gedunin in diabetic nephropathy of Streptozotocin induced diabetic rats.Journal of diabetes and metabolic disorders · 2022Article
3 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetic nephropathy is a long-term complication of diabetic mellitus. Many experimental evidences suggest that persistent hyperglycaemia generates intracellular reactive oxygen species (ROS) and upregulates transforming growth factor-b1 and extracellular matrix expression in mesangial and tubular epithelial cells, which is involved of free radicals in the pathogenesis of diabetes and more importantly in the development of diabetic complications. Antioxidants effectively inhibit high-glucose- and H2O2-induced transforming growth factor-b1 and fibronectin upregulation, thus providing evidence that ROS play an important role in high glucose-induced renal injury. The flavonoid luteolin has been shown to possess direct antioxidant activity, therefore we hypothesize that it may be useful in treatment of many chronic disease associated with oxidative stress, such as diabetic nephropathy via its antioxidant properties. Our results suggested that protection against development of diabetic nephropathy by luteolin treatment involved changes in superoxide dismutase (SOD) activity, the malondialdehyde (MDA) content and expression of Heme Oxygenase-1 (HO-1) protein.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.